PRQR

ProQR Therapeutics N.V. NASDAQ Listed Sep 18, 2014

Healthcare ·Biotechnology ·NL · proqr.com

$1.72

After hrs $1.71 -0.76%

Mkt Cap $181.2M

52w Low $1.33 22.0% of range 52w High $3.10

50d MA $1.68 200d MA $2.01

P/E (TTM) -4.1x

EV/EBITDA -2.6x

P/B 3.3x

Debt/Equity 0.3x

ROE —

P/FCF -3.5x

RSI (14) —

ATR (14) —

Beta 0.09

50d MA $1.68

200d MA $2.01

Avg Volume 516.9K

About

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmento…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 12, 2026	AMC	-0.08	-0.09	-12.5%	1.72	+0.6%	+5.8%	+2.3%	+2.9%	+0.0%	-7.6%	—
Nov 6, 2025	AMC	-0.10	-0.12	-20.0%	2.21	-2.7%	+0.5%	-2.3%	-2.3%	-2.3%	-2.3%	—
Aug 7, 2025	AMC	-0.08	-0.14	-75.0%	2.05	+2.0%	+5.9%	-7.8%	-6.8%	-1.5%	-1.5%	—
May 8, 2025	AMC	-0.09	-0.11	-22.2%	1.55	-0.6%	+3.9%	+2.6%	-1.3%	+0.0%	+5.2%	—
Mar 13, 2025	AMC	-0.10	-0.10	+0.0%	1.74	+2.3%	-2.9%	-2.3%	-5.7%	-6.3%	-6.3%	—
Nov 7, 2024	AMC	-0.12	-0.11	+8.3%	3.57	+3.6%	+5.6%	+10.9%	+11.5%	+10.9%	+10.6%	—
Aug 8, 2024	AMC	-0.12	-0.03	+75.0%	2.06	-2.9%	-2.9%	-2.9%	-2.4%	+8.7%	+8.3%	—
May 9, 2024	AMC	-0.12	-0.10	+16.7%	2.00	+0.0%	-1.0%	-1.0%	-0.5%	-4.5%	-4.0%	—
Mar 13, 2024	AMC	-0.08	-0.08	+0.0%	2.33	+0.9%	-0.4%	+9.9%	+6.0%	+7.7%	+6.0%	—
Nov 7, 2023	AMC	-0.06	-0.08	-33.3%	1.35	+8.1%	+0.0%	+3.0%	+0.7%	+3.7%	+8.9%	—
Aug 3, 2023	AMC	-0.12	-0.11	+8.3%	1.43	+0.7%	+5.6%	-0.7%	-4.9%	+4.2%	+7.0%	—
May 16, 2023	AMC	-0.12	-0.12	+0.0%	1.78	+0.0%	-1.7%	-2.2%	+5.6%	+7.3%	+4.5%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 9	Chardan Capital	Maintains	Buy → Buy	—	$1.83	$1.88	+2.7%	+8.2%	+1.1%	-1.6%	+8.7%	+8.7%
Nov 4	Chardan Capital	Maintains	Buy → Buy	—	$2.59	$2.50	-3.5%	-8.1%	-8.1%	-14.7%	-14.3%	-16.6%
Aug 8	Chardan Capital	Maintains	Buy → Buy	—	$2.05	$2.09	+2.0%	+5.9%	-7.8%	-6.8%	-1.5%	-1.5%
Jun 27	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$2.16	$2.20	+1.9%	-5.6%	-5.6%	-6.9%	-1.4%	+0.9%
Jun 27	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$2.16	$2.20	+1.9%	-5.6%	-5.6%	-6.9%	-1.4%	+0.9%
May 13	Oppenheimer	Maintains	Outperform → Outperform	—	$1.59	$1.60	+0.6%	-3.8%	-2.5%	+2.5%	+1.9%	+7.5%
Mar 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.74	$1.78	+2.3%	-2.9%	-2.3%	-5.7%	-6.3%	-6.3%
Mar 14	Chardan Capital	Maintains	Buy → Buy	—	$1.74	$1.78	+2.3%	-2.9%	-2.3%	-5.7%	-6.3%	-6.3%
Dec 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.38	$3.40	+0.6%	-2.7%	-16.3%	-26.9%	-13.0%	-24.0%
Dec 12	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$3.38	$3.40	+0.6%	-2.7%	-16.3%	-26.9%	-13.0%	-24.0%
Dec 12	Chardan Capital	Maintains	Buy → Buy	—	$3.38	$3.40	+0.6%	-2.7%	-16.3%	-26.9%	-13.0%	-24.0%
Nov 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$3.57	$3.70	+3.6%	+5.6%	+10.9%	+11.5%	+10.9%	+10.6%
Oct 29	Raymond James	Upgrade	Outperform → Strong Buy	—	$3.31	$3.70	+11.8%	+4.2%	+10.6%	+5.7%	+12.7%	+9.7%
May 10	Chardan Capital	Maintains	Buy → Buy	—	$2.00	$2.00	+0.0%	-1.0%	-1.0%	-0.5%	-4.5%	-4.0%
May 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.00	$2.00	+0.0%	-1.0%	-1.0%	-0.5%	-4.5%	-4.0%
Apr 18	Citigroup	Maintains	Neutral → Neutral	—	$1.90	$1.94	+2.1%	-2.1%	+4.7%	+5.3%	+6.3%	+5.8%
Mar 14	Chardan Capital	Maintains	Buy → Buy	—	$2.33	$2.35	+0.9%	-0.4%	+9.9%	+6.0%	+7.7%	+6.0%
Mar 14	HC Wainwright& Co.	Maintains	Buy → Buy	—	$2.33	$2.35	+0.9%	-0.4%	+9.9%	+6.0%	+7.7%	+6.0%
Mar 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.33	$2.35	+0.9%	-0.4%	+9.9%	+6.0%	+7.7%	+6.0%
Nov 8	Chardan Capital	Upgrade	Neutral → Buy	—	$1.35	$1.46	+8.1%	+0.0%	+3.0%	+0.7%	+3.7%	+8.9%
Nov 8	Raymond James	Maintains	Outperform → Outperform	—	$1.35	$1.46	+8.1%	+0.0%	+3.0%	+0.7%	+3.7%	+8.9%
Sep 18	Citigroup	Maintains	Buy → Buy	—	$1.61	$1.61	+0.0%	-4.3%	-4.3%	-8.1%	-8.1%	-8.7%
Aug 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.51	$1.51	+0.0%	-6.0%	-9.9%	-1.3%	+1.3%	+1.3%
Aug 4	Chardan Capital	Maintains	Neutral → Neutral	—	$1.43	$1.44	+0.7%	+5.6%	-0.7%	-4.9%	+4.2%	+7.0%
May 17	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$1.78	$1.78	+0.0%	-1.7%	-2.2%	+5.6%	+7.3%	+4.5%
May 17	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$1.78	$1.78	+0.0%	-1.7%	-2.2%	+5.6%	+7.3%	+4.5%
May 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.78	$1.78	+0.0%	-1.7%	-2.2%	+5.6%	+7.3%	+4.5%
Mar 30	HC Wainwright & Co.	Maintains	Buy → Buy	—	$2.52	$2.56	+1.6%	-21.0%	-15.5%	-10.7%	-13.1%	-11.9%
Dec 23	Raymond James	Maintains	Outperform → Outperform	—	$2.70	$2.57	-4.8%	+0.4%	+19.3%	+13.3%	+24.8%	+37.0%
Dec 22	Cantor Fitzgerald	Upgrade	Neutral → Overweight	—	$1.65	$2.72	+64.8%	+63.6%	+64.2%	+95.2%	+85.5%	+104.2%
Aug 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.86	$0.87	+0.9%	+3.5%	+1.2%	-1.2%	-4.0%	-5.0%
Aug 12	Chardan Capital	Downgrade	Buy → Neutral	—	$0.81	$0.85	+4.3%	+5.5%	+9.2%	+6.7%	+4.3%	+1.3%
Aug 12	Raymond James	Upgrade	Market Perform → Outperform	—	$0.81	$0.85	+4.3%	+5.5%	+9.2%	+6.7%	+4.3%	+1.3%
May 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$0.64	$0.65	+0.8%	-8.9%	-7.7%	-12.5%	-8.1%	-3.1%
May 6	Chardan Capital	Maintains	Buy → Buy	—	$0.67	$0.66	-1.5%	-4.5%	-13.0%	-11.8%	-16.4%	-12.2%
Apr 14	Chardan Capital	Maintains	Buy → Buy	—	$0.79	$0.80	+1.3%	-0.4%	-5.6%	-3.8%	-3.2%	-4.3%
Apr 14	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$0.79	$0.80	+1.3%	-0.4%	-5.6%	-3.8%	-3.2%	-4.3%
Feb 14	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$1.39	$1.36	-2.2%	-10.1%	-9.4%	-12.2%	-13.7%	-12.2%
Feb 14	HC Wainwright & Co.	Maintains	Buy → Buy	—	$1.39	$1.36	-2.2%	-10.1%	-9.4%	-12.2%	-13.7%	-12.2%
Feb 14	Chardan Capital	Maintains	Buy → Buy	—	$1.39	$1.36	-2.2%	-10.1%	-9.4%	-12.2%	-13.7%	-12.2%
Feb 14	Raymond James	Downgrade	Strong Buy → Market Perform	—	$1.39	$1.36	-2.2%	-10.1%	-9.4%	-12.2%	-13.7%	-12.2%
Aug 9	Chardan Capital	Maintains	Buy → Buy	—	$6.26	$6.32	+1.0%	+0.2%	-0.2%	+0.6%	+5.6%	+0.5%
Aug 11	Chardan Capital	Maintains	Buy → Buy	—	$5.45	$5.50	+0.9%	+4.0%	-2.4%	-3.7%	-3.3%	-5.3%
Nov 19	Citi	Maintains	Buy → Buy	—	$6.25	$6.27	+0.3%	+6.6%	+23.0%	+30.9%	+34.4%	+32.0%
Nov 19	Citigroup	Maintains	Buy → Buy	—	$6.25	$6.27	+0.3%	+6.6%	+23.0%	+30.9%	+34.4%	+32.0%
Sep 26	Leerink Swann	Maintains	Outperform → Outperform	—	$6.45	$6.05	-6.2%	-19.4%	-20.2%	-24.8%	-24.8%	-25.6%
Mar 15	JMP Securities	Maintains	Market Outperform → Market Outperform	—	$4.69	$4.89	+4.3%	-0.2%	-6.6%	-12.4%	-9.0%	-7.2%

Recent Filings

8-K

Lyell Immunopharma, Inc. -- 8-K Filing

Lyell Immunopharma appointed a new executive officer with participation in the company's severance plan, potentially affecting shareholder equity structure and executive compensation costs.

Mar 9

Data updated apr 26, 2026 8:50pm · Source: massive.com